Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.31 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | BCR | P11274 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | MAT2A | P31153 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.30 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10767571 | 0.78 | — | — | |
| SCHEMBL25154463 | 0.75 | GRIN2B (0.32) | — | |
| SCHEMBL30785420 | 0.75 | GRIN2B (0.32) | — | |
| SCHEMBL24835490 | 0.73 | GAA (0.41) | XDHHTTTGFBR1GAAKMT2A | |
| SCHEMBL25098948 | 0.73 | ALDH1A1 (0.39) | XDHGAAKMT2ANR3C1 | |
| SCHEMBL25154222 | 0.73 | XDH (0.37) | XDHMAPTTSHRRECQLNPSR1 | |
| SCHEMBL30316641 | 0.73 | XDH (0.41) | XDHHASPINHPGD | |
| SCHEMBL29489066 | 0.73 | ALDH1A1 (0.39) | XDHGAAKMT2ANR3C1 | |
| SCHEMBL256369 | 0.71 | PI4KA (0.39) | KMT2A | |
| SCHEMBL23507946 | 0.71 | XDH (0.36) | XDHPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542297-B2 | Compositions and methods for treating CNS disorders | SAGE THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11530237-B2 | Compositions and methods for treating CNS disorders | SAGE THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20220220150-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2022-07-14 | — | — | US | disclosed |
| US-20200392177-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2020-12-17 | — | — | US | disclosed |
| US-10577390-B2 | Compositions and methods for treating CNS disorders | SAGE THERAPEUTICS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20170240589-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2017-08-24 | — | — | US | disclosed |
| US-20110059976-A1 | PYRIDO PYRIMIDINONES, DIHYDRO PYRIMIDO PYRIMIDINONES AND PTERIDINONES USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530237-B2 | Compositions and methods for treating CNS disorders | ADRA1B, ADRA2B, ADRA1A | XDH 2473/4885HTT 1756/4885TGFBR1 1425/4885 |
| US-10577390-B2 | Compositions and methods for treating CNS disorders | ADRA1B, ADRA2B, GRIN2B | XDH 2511/4885HTT 1726/4885TGFBR1 1672/4885 |
| US-20220220150-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | ADRA1B, ADRA2B, ADRA1A | XDH 2478/4885HTT 1772/4885TGFBR1 1413/4885 |
| US-20200392177-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | ADRA1B, ADRA2B, ADRA1A | XDH 2473/4885HTT 1756/4885TGFBR1 1425/4885 |
| US-20170240589-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | ADRA1B, ADRA2B, ADRA1A | XDH 2560/4885HTT 1792/4885TGFBR1 1649/4885 |
| US-11542297-B2 | Compositions and methods for treating CNS disorders | ADRA1B, ADRA2B, ADRA1A | XDH 2478/4885HTT 1772/4885TGFBR1 1413/4885 |
| US-20110059976-A1 | PYRIDO PYRIMIDINONES, DIHYDRO PYRIMIDO PYRIMIDINONES AND PTERIDINONES USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | XDH 578/4885HTT 4600/4885TGFBR1 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.